Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Oppenheimer analyst Matthew Biegler has maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL) with a price target of $9.00, while the stock closed at $1.32. The overall analyst consensus for Zentalis is a Moderate Buy, with an average price target of $10.00. Biegler has a -4.2% average return and a 38.97% success rate on his stock recommendations.
In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Buy rating on Zentalis Pharmaceuticals, with a price target of $9.00. The company’s shares closed yesterday at $1.32.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Biegler covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, CytomX Therapeutics, and Nurix Therapeutics. According to TipRanks, Biegler has an average return of -4.2% and a 38.97% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zentalis Pharmaceuticals with a $10.00 average price target.
